Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
JDR Clinical and Translational Research|April 2, 2019
Health State Utilities in Edentulous Patients: A Time Trade-off ApproachP Sendi, N Oppliger, F Chakroun, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 13, 2005
Dynamics of serum procalcitonin in patients after major neurosurgeryG Laifer, M Wasner, P Sendi, et al.
AIDS (London, England)|April 10, 1999
Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trialsH C Bucher, L E Griffith, G H Guyatt, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 6, 2005
Genotypic and phenotypic resistance testing of HIV-1 in routine clinical careH H Hirsch, H Drechsler, A Holbro, et al.
The Journal of Hospital Infection|July 19, 2011
Group B streptococcus in prosthetic hip and knee joint-associated infectionsP Sendi, B Christensson, I Uçkay, et al.
AIDS (London, England)|July 9, 1999
Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort StudyP P Sendi, H C Bucher, T Harr, et al.
The Journal of Antimicrobial Chemotherapy|December 11, 1999
Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort StudyP P Sendi, B A Craig, G Meier, et al.
Diabetologia|February 15, 2000
The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspectiveA J Palmer, C Weiss, P P Sendi, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 12, 1999
Rare AIDS-defining diseases in the Swiss HIV Cohort StudyB Burckhardt, P Sendi, D Pfluger, et al.
Expert Opinion on Investigational Drugs|September 13, 2002
Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countriesGilbert R Kaufmann, Don Smith, Heiner C Bucher, et al.
Pageof 5